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Running title:   The Role of KRAS in Endometrial Cancer (Review) 
  
Abstract. Endometrial cancer (EC) is the most common cancer of the female genital 
tract, resulting annually in 76,000 related deaths worldwide. EC originates either 
from oestrogen-related proliferative endometrium (type I, endometrioid), or from 
atrophic endometrium (type II, non-endometrioid). Each type of EC is characterized 
by different molecular profile alterations. The Kirsten rat sarcoma viral oncogene 
homolog (KRAS) gene encodes a signalling protein which moderates response to 
various extracellular signals via down-regulation of the mitogen-activated protein 
kinase (MAPK) or phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene 
(PI3K/AKT) pathways. This article reviews the role of KRAS in predicting transition 
from hyperplastic endometrium to early-stage well-differentiated EC, as well as 
further invasive proliferation of the tumour to advanced-stage disease. KRAS seems 
to be directly associated with type I EC, and most studies support its early 
involvement in carcinogenesis. Current evidence correlates KRAS mutations with 
increased cell proliferation and apoptosis, as well as up-regulation of endometrial cell 
oestrogen receptors. Tumours positive for KRAS mutation can harbour 
hypermethylation-related changes in genome expression, and this can be the cause 
of concurrent loss of DNA repair proteins. Despite some evidence that KRAS 
mutation status affects cancer progression, a consensus is yet to be reached. Based 
on the available evidence, we suggest that screening for KRAS mutations in patients 
with hyperplastic endometrium or early-stage type I EC, may provide important 
information for prognosis stratification, and further provision of personalised 
treatment options.  
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Endometrial Cancer (EC) is the most common cancer of the female genital tract in 
developed countries (1). Each year 319,500 women are diagnosed with EC resulting 
in 76,000 deaths worldwide (2). EC develops from the inner lining of the uterine corpus 
(3), and it is currently divided into two types as firstly described by Llobet  et al. (4). 
Type I tumours tend to be low or intermediate tumour grade; they overlap considerably 
(80%) with oestrogen-related endometrioid carcinomas. Contrary to type I, type II EC 
results from a sequence of genetic alterations occurring in atrophic endometrium; this 
can occasionally reflect a progression from polyps or pre-cancerous lesions to EC. 
Type II EC is mostly considered as non-endometrioid serous carcinomas (4); it tends 
to be high grade, deeply invasive into the myometrium, and of more advanced stage 
at presentation (4, 5). The estimated 5-year overall survival for patients with any type 
of EC is 81.5% (any stage) (6).  
 
Current Staging 
EC staging consensus keeps with the 2009 International Federation of Gynaecology 
and Obstetrics (FIGO) revised classification. Revised FIGO staging defines four 
stages (I-IV) following radical surgical resection (7). Stage I refers to a uterus-confined 
tumour, stage II to involvement of the cervix, stage III to adnexal or lymph node 
involvement, and stage IV to the presence of any metastatic deposits outside the 
pelvis (7).  
 
Treatment Stratification 
To-date, the stratification of treatment options relies on the disease stage; this includes 
certain histopathological features which are integrated into the FIGO staging. The 
cornerstone of EC treatment is to offer (radical) excision of the tumour; this includes 
total hysterectomy with/without bilateral salpingo-oophorectomy, and if indicated, 
systematic pelvic/para-aortic lymphadenectomy. Besides its role in treatment, radical 
surgery is also the basis for staging and stratifying patients for further adjuvant 
treatment options (8-10). Gupta et al. suggest an EC risk group classification; this is 
primarily based on disease staging after primary resection and stratifies the need for 
further adjuvant treatment depending on the potential for disease recurrence (11). 
Adjuvant treatment options include chemo-radiotherapy, pelvic external beam 
radiation therapy or vaginal cuff brachytherapy. Based on this model, surgery is the 
only treatment in early, low-risk EC, whereas intermediate high-risk EC would require 
additional adjuvant treatment (11). 
 
Molecular Staging 
Although FIGO remains the gold standard in EC staging, there is an increasing need 
to identify novel molecular biomarkers in order to achieve individualised treatment 
options. Several efforts have been described in the literature, however, consensus is 
yet to be reached. All efforts aim to provide a more accurate framework which can 
predict both prognosis as well as response to treatment and the need for additional 
adjuvant therapy schemes.  
 A classic example is The Cancer Genome Atlas (TCGA) classification. TCGA 
provides a molecular taxonomy for EC based on an integrated multi-platform 
incorporating genomic, transcriptomic and proteomic profiling (1, 12). TCGA classifies 
EC into four groups, each of which is based on different histopathology or molecular 
sub-type, as well as prognostic potential. Group 1 includes tumours with a 
hypermutant profile and mainly DNA polymerase epsilon, catalytic subunit (POLE) 
exonuclease inactivation mutations, which have a favourable overall prognosis. Group 
2 refers to EC which is associated with microsatellite instability (MSI), and more 
specifically with hypermethylation of the promoter region of the mutL homolog 1 
(MLH1) gene; the latter has been found to be the primary MSI-associated mechanism 
of carcinogenesis in sporadic colorectal cancer (CRC) (13). Group 3 includes tumours 
with low somatic copy number alterations (SCNA); the latter refers to various 
segmental aneuploidies, focal events, and whole-chromosome aneuploidies (14). 
SCNA are strongly associated with chromosomal instability; these mechanisms 
explain why cancer cells can potentially deviate from a diploid karyotype and can also 
be the fundamental cause for a degree of general heterogeneity within an individual 
tumour. Groups 2 and 3 have similar prognosis. Group 4 represents a high SCNA 
group, which mostly incorporates TP53 mutation, and includes serous-like EC, 
indicating a poor overall prognosis.  
 Further to stratifying prognosis, the incorporation of molecular features into the 
classification of EC aims to optimise personalised treatment options and to predict 
potential responses to (neo)adjuvant treatment (12). Recent studies have shown that 
in the case of Kirsten rat sarcoma viral oncogene homolog (KRAS)-mutant EC, a 
combination therapy of mitogen-activated extracellular kinase (MEK) inhibitors plus 
anti-oestrogen agents may alter oestrogen signalling and thus improve the response 
rate (15).  
 
KRAS: A Marker in Cancer Molecular Biology  
KRAS is a proto-oncogene (Gene ID: 3845) located at chromosome 12 (12p12.1) and 
is primarily involved in the cellular response to extracellular signals. It is strongly 
associated with down-regulation of mitogen-activated protein kinase (MAPK) and 
phosphoinositide-3-kinase/v-akt murine thymoma viral oncogene (PI3K/AKT) 
pathways (16-18). KRAS encodes a 21_kDa signalling protein which connects 
activated membrane receptors to MAPK and PI3K/AKT pathways (5). Mutant KRAS 
promotes down-regulation of MAPK or PI3K/AKT, which further results in excessive 
cell proliferation and subsequently in carcinogenesis (5). KRAS mutations refer to a 
frequent alteration of guanine to adenine (G>A), a mutation most frequently found in 
codon 12. Codons 12 and 13 in exon 2 constitute 90% of all KRAS mutations (19). In 
total, there have been 85 different mutations reported, many of which are pathway-
specific (20).  
 KRAS is tethered to several cell membrane receptors and acts as a signalling 
transducer molecule. A classic example of such receptors are the surface tyrosine 
kinase receptors, including the epidermal growth factor receptor (EGFR) across the 
cell membrane of colonic and rectal epithelial cells. There is a large family of anti-
EGFR chemotherapy agents, for example cetuximab and panitumumab, which target 
these receptors. KRAS mutations can cause resistance to EGFR inhibitors (20). 
Hence, especially in the case of CRC, KRAS-mutant status is directly associated with 
chemotherapy resistance. Therefore, KRAS is currently being used in clinical practice 
as a predictive biomarker for response to anti-EGFR chemotherapy agents (21-25).  
 
KRAS Mutations as Biomarkers of Early-stage Type I EC 
Type I and II EC are thought to be associated with different distinct mutations (4, 5). 
KRAS mutations have been mostly associated with type I oestrogen-related EC and 
their frequency is estimated at around 10-30% (4, 5).  
 In their review of mechanisms of EC development, Banno et al. supported the 
assumption that KRAS mutations occur at the early stages of the EC pathway (5). 
Further to this, KRAS mutations are present in 6-16% of endometrial hyperplasia 
specimens (26). Similar notions have been discussed in the case of CRC, where in 
the classic adenoma–carcinoma pathway, KRAS mutations seem to appear early in 
the neoplastic route. Several studies concluded that KRAS may play a significant role 
in early stage CRC (27-29). In 1988, Vogelstein et al. stated that early mutations of 
adenomatous polyposis coli gene result in deregulation of the wingless-related 
integration site (WNT) pathway (30); KRAS mutations follow deregulation of the WNT 
pathway and certainly take place prior to TP53 gene inactivation. Similarly, in the case 
of EC, KRAS mutations appear to be a stage ahead of TP53 involvement, and TP53 
signifies the transition from low-grade to high-grade type I EC (5).  
 Further to this, Tsuda et al. stress the role of KRAS in predicting invasive 
proliferation of well-differentiated (grade I) tumours (31). Therefore, the role of KRAS 
in both an early checkpoint of transition from hyperplasia to EC, as well as a marker 
of the invasive potential in the case of grade I tumours, is clear.    
 Another interesting feature is the association of KRAS mutations with MSI-
positive EC. Microsatellites are short repetitive DNA sequences which are involved in 
the DNA repair system. The vast majority of MSI involvement is either via direct base 
substitutions (point mutations), or via hypermethylation of promoters of involved genes 
(epigenetic changes). In the case of Lynch syndrome, the whole series of mismatch 
repair (MMR) genes, including MLH1, mutS homolog 2 (MSH2), mutS homolog 6 
(MSH6) and post-meiotic segregation increased 2 (PMS2), is affected (13). 
Nevertheless, in sporadic CRC and type I EC, MMR defects are primarily a 
consequence of hypermethylation of gene promoters, and this primarily affects the 
MLH1 (4, 13). A classic example was shown by Muraki  et al., who reported 
hypermethylation of MLH1 promoter in 40% of type I ECs (32). KRAS promoter can 
equally be affected by hypermethylation and this can explain its concurrent presence 
with defective expression of MMR genes (in MSI-positive EC). Both hypermethylation 
changes, as reflected by reduced presence of DNA repair proteins (MMR), and KRAS 
mutations, are generally thought to occur early in the EC pathway.  
  
Translation of KRAS Mutation Status into Clinical Information for Type I EC  
A narrative review of the literature was performed to summarize the current views on 
the prognostic and predictive value of KRAS mutations in EC. PubMed database was 
searched using any (AND, OR) combination of keywords “KRAS” and “Endometrial 
Cancer”. Any original study which involved KRAS mutation in EC was identified and 
critically commented on. 
 Most studies focus on explaining the role of KRAS in type I oestrogen-related 
EC. van der Putten et al. supported the view that KRAS mutations are found adjacent 
to hyperplastic endometrial tissue (33). Based on this, KRAS status was used as a 
prognostic marker to describe a possible transition from hyperplastic tissue to 
malignancy; 27% of their type I EC specimens were positive for KRAS mutation, most 
of which were next to hyperplastic endometrium. In 5% of cases, hyperplastic (non-
malignant) endometrial specimens were also positive for KRAS mutation.  Further to 
this study, Zauber et al. supported the involvement of KRAS early in the 
carcinogenesis pathway, suggesting that biopsies confirming endometrial hyperplasia 
should be analysed for KRAS status, along with MSI status (34). Similarly, Berg et al. 
concluded that KRAS involvement happens early, and that molecular alterations 
related to KRAS mutations and inflammation are more common in obese patients (35). 
Similarly, Duggan et al. concluded that there is early-stage involvement of KRAS gene 
in type I EC, prior to clonal expansion (36).      
 Many studies correlated KRAS status with certain histopathological features; 
Xiong et al. supported the role of KRAS mutations in the formation of superficial 
epithelial changes in endometrioid EC, which has been further associated with focal 
mucinous differentiation (37). A similar association between KRAS and mucinous 
differentiation was reported by He et al. (38). Another interesting study by Steward et 
al. identified KRAS mutations in 12  out of 42 endometriosis-associated endometrioid 
adenocarcinomas (39).  
 As discussed previously, current literature concludes that KRAS mutations are 
primarily found in type I oestrogen-related EC (5). An interesting question would be to 
explore the relationship between the KRAS gene and oestrogen receptors (ER), as 
there is extremely limited evidence for this. Tu et al. supported the assumption that the 
transcriptional activity of the ER is up-regulated by KRAS mutation (40). In other 
words, ER expression may be seen as a regulator of the RAS signalling pathway which 
directly affects directly the tumorigenesis of EC. 
 Several studies support the role of KRAS as a potential prognostic marker, both 
in terms of transition from pre-malignant to malignant cell status, as well as 
progression from early to more advanced invasive cancer. Ninomiya et al. identified 
K- and NRAS-mediated signalling pathways as potential inducers of cell apoptosis 
(41). Birkeland et al. noted an increase in KRAS amplification and KRAS mRNA 
expression during transition from primary to metastatic disease (42). Alexander-Sefre 
et al. suggests a molecular assessment of the depth of myometrial invasion of EC 
based on KRAS (43). Mizuuchi et al. correlated the presence of KRAS mutation (codon 
12 or 13) with poor prognosis (44). Ito et al. attributed KRAS mutations as being 
responsible for more aggressive clinical behaviour of EC in postmenopausal women 
(type II EC) (45). On the other hand, Varras et al. (46) and Trowbridge et al. (47) did 
not find correlation of KRAS status with any clinicopathological features. From the 
aforementioned evidence, it is apparent that a consensus on the exact way that KRAS 
overall affects EC prognosis is yet to be achieved.  
 Another interesting question is the association of KRAS status following 
tamoxifen exposure after breast cancer. Wallen et al. supported the existence of a link 
between tamoxifen use and KRAS codon 12 mutation (48). Nagy et al. noted a higher 
trend in KRAS mutation following exposure to tamoxifen (49). 
 Finally, although KRAS has an established predictive value in CRC, there are 
extremely limited data on this aspect in the case of EC. Byron et al. state that KRAS 
and fibroblast growth factor receptor 2 (FGFR2) mutations may alter the effectiveness 
of anti-FGR or anti-MEK biological therapies (50). 
 A promising study by Alomari et al. showed that KRAS mutation had a positive 
predictive value of 88% in diagnosing complex atypical hyperplasia (51). Based on the 
previous discussion, this could be an extremely important finding which may alter the 
current management of endometrial hyperplasia. Current practice in the United 
Kingdom, as defined by the Green-top guideline (No. 67), suggests first line 
management of endometrial hyperplasia with atypia in premenopausal women who 
wish to maintain fertility, by offering the Levonorgestrel Intrauterine System (LNG-IUS) 
and second-line by administering oral progestogen supplements or combination of 
both for at least 6 months (52). Identifying novel biomarkers which can predict the 
course of lesions and their progression to EC would be useful to optimise care 
provision and reduce anxiety from both the patient’s and clinician’s point of view. 
 
Limitations  
We recognise a series of limitations in this narrative mini-review. Although PubMed 
was searched systematically using certain key words, only the studies that were 
thought to be relevant and of high quality were considered in raising the discussion 
points. Secondly, most of the included cohorts were small with several limitations. 
Furthermore, existing evidence was conflicting. Lastly, a single biomarker was 
searched, which may provide a biased view as it may be optimistic to explain a 
complex carcinogenesis progression using a single gene.   
 
Conclusions and Future Endeavours  
Table I summarises the current knowledge on the role of KRAS in EC. Although 
evidence is limited and occasionally conflicting, there is a clear trend in the literature 
showing that KRAS plays a role early in EC progression, especially when the disease 
originates from hyperplastic endometrium. Given the lack of focused biomarkers, it 
would be interesting to conduct a prospective cohort study to delineate the role of 
KRAS in predicting response of hyperplasia to standard treatment or cancer 
progression after hyperplasia with or without atypia. In conclusion, findings of this 
review may allow for revision of the current management of pre-malignant endometrial 
lesions, especially hyperplasia with or without atypia. Screening of such cases for 
KRAS mutation would allow individualisation of treatment approach via flagging 
potentially high-risk pre-malignant cases for relapse of hyperplasia or future cancer 
progression. 
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Table I. Summary of the role of Kirsten rat sarcoma viral oncogene homolog (KRAS) mutation in endometrial cancer (EC).  
I General information 
 KRAS is a proto-oncogene primarily involved 
in cellular response to several signals; 
 
Most authors describe KRAS as a signalling 
transducer protein molecule. 
Mutations cause down-
regulation of 
MAPK/PI3K/AKT pathway 
Location: 12p12.1 
Encodes: 21 kDa 
protein 
Mutation: G>A, most 
common at codon 12, 
13 (90%); 85 different 
mutations in total 
Involved in several 
carcinogenesis pathways 
(lung, CRC, endometrial etc.); 
most authors attribute KRAS 
mutations to being fairly early 
in the process 
II What we know about KRAS 
 Associated with type I 
EC (endometrioid) and 
subsequently 
hyperplastic 
endometrium; 
supposed to be an 
early stage mutation. 
Can be present with 
hypermethylation of 
mismatch repair gene 
promoters (MLH1 
gene); therefore, 
associated with 
microsatellite 
unstable EC 
Mutations present in 6-16% 
of endometrial hyperplasia 
specimens; and 10-30% of 
type I EC. 
Positive predictive value of 
88% in diagnosing complex 
atypical hyperplasia 
Potentially dual role: 
-Transition from 
hyperplastic 
endometrium to early 
stage malignancy 
- Progression from 
early to more advanced 
invasive cancer. 
Relationship with ER: 
Transcriptional activity of the 
ER might be up-regulated by 
KRAS mutations. 
III What we do not know about KRAS 
 Prognostic and 
predictive (response to 
chemotherapy) value 
still equivocal for EC. 
Limited use in clinical 
practice. 
Limited value in type II non-
endometrioid EC 
Association of KRAS 
and non-malignant 
conditions i.e. 
endometriosis 
Association of KRAS mutations 
with exposure to tamoxifen 
following breast cancer 
chemotherapy. 
IV Future Directions – Applicability in Clinical Practice 
 Can we screen endometrial hyperplastic 
specimens for KRAS to flag high-risk cases for 
potential transition to malignancy? 
Could KRAS predict response to (neo)adjuvant 
chemotherapy?  
 
Could we stratify need for adjuvant treatment options 
following early-stage type I EC based on KRAS 
mutation (high risk for aggressive EC pattern). 
Should KRAS be included as a 
screening tool for polyps or 
other (pre-/non-)malignant 
conditions i.e. endometriosis in 
pre-menopausal women? 
ER: Oestrogen receptor; MAPK/PI3K/AKT; MLH1: mitogen-activated protein kinase/phosphoinositide-3-kinase/v-akt murine 
thymoma viral oncogene; MLH1: mutL homolog 1. 
 1 Piulats JM, Guerra E, Gil-Martin M, Roman-Canal B, Gatius S, Sanz-Pamplona R, Velasco A, Vidal A and Matias-Guiu X: Molecular approaches for classifying 
endometrial carcinoma. Gynecol Oncol 145(1): 200-207, 2017. 28040204, 10.1016/j.ygyno.2016.12.015 
2 Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D and Bray F: Cancer incidence and mortality worldwide: Sources, 
methods and major patterns in globocan 2012. Int J Cancer 136(5): E359-386, 2015. 25220842, 10.1002/ijc.29210 
3 Linda S. Cook NSW, Jennifer S. Doherty, Chu Chen: Endometrial cancer. Cancer Epidemiology and Prevention, 2006. 
10.1093/acprof:oso/9780195149616.003.0053 
4 Llobet D, Pallares J, Yeramian A, Santacana M, Eritja N, Velasco A, Dolcet X and Matias-Guiu X: Molecular pathology of endometrial carcinoma: Practical 
aspects from the diagnostic and therapeutic viewpoints. J Clin Pathol 62(9): 777-785, 2009. 18977806, 10.1136/jcp.2008.056101 
5 Banno K, Yanokura M, Iida M, Masuda K and Aoki D: Carcinogenic mechanisms of endometrial cancer: Involvement of genetics and epigenetics. J Obstet 
Gynaecol Res 40(8): 1957-1967, 2014. 25131761, 10.1111/jog.12442 
6 Institute NC: Dccps, surveillance research program, surveillance systems branch 
. SEER*Stat Database: Incidence  
7 Creasman W: Revised figo staging for carcinoma of the endometrium. Int J Gynaecol Obstet 105(2): 109, 2009. 19345353, 10.1016/j.ijgo.2009.02.010 
8 group As, Kitchener H, Swart AM, Qian Q, Amos C and Parmar MK: Efficacy of systematic pelvic lymphadenectomy in endometrial cancer (mrc astec trial): 
A randomised study. Lancet 373(9658): 125-136, 2009. 19070889, 10.1016/S0140-6736(08)61766-3 
9 Mariani A, Dowdy SC, Cliby WA, Gostout BS, Jones MB, Wilson TO and Podratz KC: Prospective assessment of lymphatic dissemination in endometrial 
cancer: A paradigm shift in surgical staging. Gynecol Oncol 109(1): 11-18, 2008. 18304622, 10.1016/j.ygyno.2008.01.023 
10 Kong A, Johnson N, Kitchener HC and Lawrie TA: Adjuvant radiotherapy for stage i endometrial cancer: An updated cochrane systematic review and 
meta-analysis. J Natl Cancer Inst 104(21): 1625-1634, 2012. 22962693, 10.1093/jnci/djs374 
11 Gupta D: Clinical behavior and treatment of endometrial cancer. Adv Exp Med Biol 943(47-74, 2017. 27910064, 10.1007/978-3-319-43139-0_2 
12 Cancer Genome Atlas Research N, Kandoth C, Schultz N, Cherniack AD, Akbani R, Liu Y, Shen H, Robertson AG, Pashtan I, Shen R, Benz CC, Yau C, Laird 
PW, Ding L, Zhang W, Mills GB, Kucherlapati R, Mardis ER and Levine DA: Integrated genomic characterization of endometrial carcinoma. Nature 
497(7447): 67-73, 2013. 23636398, 10.1038/nature12113 
13 Sideris M and Papagrigoriadis S: Molecular biomarkers and classification models in the evaluation of the prognosis of colorectal cancer. Anticancer Res 
34(5): 2061-2068, 2014. 24778007,  
14 Sansregret L, Vanhaesebroeck B and Swanton C: Determinants and clinical implications of chromosomal instability in cancer. Nat Rev Clin Oncol 15(3): 
139-150, 2018. 29297505, 10.1038/nrclinonc.2017.198 
15 Ring KL, Yates MS, Schmandt R, Onstad M, Zhang Q, Celestino J, Kwan SY and Lu KH: Endometrial cancers with activating kras mutations have activated 
estrogen signaling and paradoxical response to mek inhibition. Int J Gynecol Cancer 27(5): 854-862, 2017. 28498246, 
10.1097/IGC.0000000000000960 
16 Church D, Midgley R and Kerr D: Biomarkers in early-stage colorectal cancer: Ready for prime time? Dig Dis 30 Suppl 2(27-33, 2012. 23207929, 
10.1159/000341890 
17 Lee LJ, Ratner E, Uduman M, Winter K, Boeke M, Greven KM, King S, Burke TW, Underhill K, Kim H, Boulware RJ, Yu H, Parkash V, Lu L, Gaffney D, Dicker 
AP and Weidhaas J: The kras-variant and mirna expression in rtog endometrial cancer clinical trials 9708 and 9905. PLoS One 9(4): e94167, 2014. 
24732316, 10.1371/journal.pone.0094167 
18 Hershkovitz D and Ben-lzhak O: [molecular pathology - aspects in kras mutation analysis in colon carcinoma]. Harefuah 152(6): 356-360, 367, 2013. 
23885470,  
19 Rosty C, Young JP, Walsh MD, Clendenning M, Walters RJ, Pearson S, Pavluk E, Nagler B, Pakenas D, Jass JR, Jenkins MA, Win AK, Southey MC, Parry S, 
Hopper JL, Giles GG, Williamson E, English DR and Buchanan DD: Colorectal carcinomas with kras mutation are associated with distinctive 
morphological and molecular features. Mod Pathol 26(6): 825-834, 2013. 23348904, 10.1038/modpathol.2012.240 
20 Corso G, Pascale V, Flauti G, Ferrara F, Marrelli D and Roviello F: Oncogenic mutations and microsatellite instability phenotype predict specific 
anatomical subsite in colorectal cancer patients. Eur J Hum Genet 21(12): 1383-1388, 2013. 23572025, 10.1038/ejhg.2013.66 
21 Lee JK and Chan AT: Molecular prognostic and predictive markers in colorectal cancer: Current status. Curr Colorectal Cancer Rep 7(2): 136-144, 2011. 
21572547, 10.1007/s11888-011-0091-4 
22 Rizzo S, Bronte G, Fanale D, Corsini L, Silvestris N, Santini D, Gulotta G, Bazan V, Gebbia N, Fulfaro F and Russo A: Prognostic vs predictive molecular 
biomarkers in colorectal cancer: Is kras and braf wild type status required for anti-egfr therapy? Cancer Treat Rev 36 Suppl 3(S56-61, 2010. 
21129611, 10.1016/S0305-7372(10)70021-9 
23 Siena S, Sartore-Bianchi A, Di Nicolantonio F, Balfour J and Bardelli A: Biomarkers predicting clinical outcome of epidermal growth factor receptor-
targeted therapy in metastatic colorectal cancer. J Natl Cancer Inst 101(19): 1308-1324, 2009. 19738166, 10.1093/jnci/djp280 
24 Grade M, Wolff HA, Gaedcke J and Ghadimi BM: The molecular basis of chemoradiosensitivity in rectal cancer: Implications for personalized therapies. 
Langenbecks Arch Surg 397(4): 543-555, 2012. 22382702, 10.1007/s00423-012-0929-5 
25 Duffy MJ, Lamerz R, Haglund C, Nicolini A, Kalousova M, Holubec L and Sturgeon C: Tumor markers in colorectal cancer, gastric cancer and 
gastrointestinal stromal cancers: European group on tumor markers 2014 guidelines update. Int J Cancer 134(11): 2513-2522, 2014. 23852704, 
10.1002/ijc.28384 
26 Sasaki H, Nishii H, Takahashi H, Tada A, Furusato M, Terashima Y, Siegal GP, Parker SL, Kohler MF, Berchuck A and et al.: Mutation of the ki-ras 
protooncogene in human endometrial hyperplasia and carcinoma. Cancer Res 53(8): 1906-1910, 1993. 8467512,  
27 Sideris M, Moorhead J, Diaz-Cano S, Bjarnason I, Haji A and Papagrigoriadis S: Kras mutant status, p16 and beta-catenin expression may predict local 
recurrence in patients who underwent transanal endoscopic microsurgery (tems) for stage i rectal cancer. Anticancer Res 36(10): 5315-5324, 2016. 
27798894, 10.21873/anticanres.11104 
28 Sideris M, Moorhead J, Diaz-Cano S, Haji A and Papagrigoriadis S: Kras mutant status may be associated with distant recurrence in early-stage rectal 
cancer. Anticancer Res 37(3): 1349-1357, 2017. 28314302, 10.21873/anticanres.11454 
29 Ryan BM, Robles AI and Harris CC: Kras-lcs6 genotype as a prognostic marker in early-stage crc--letter. Clin Cancer Res 18(12): 3487-3488; author reply 
3489, 2012. 22669132, 10.1158/1078-0432.CCR-12-0250 
30 Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AM and Bos JL: Genetic alterations during 
colorectal-tumor development. N Engl J Med 319(9): 525-532, 1988. 2841597, 10.1056/NEJM198809013190901 
31 Tsuda H, Jiko K, Yajima M, Yamada T, Tanemura K, Tsunematsu R, Ohmi K, Sonoda T and Hirohashi S: Frequent occurrence of c-ki-ras gene mutations in 
well differentiated endometrial adenocarcinoma showing infiltrative local growth with fibrosing stromal response. Int J Gynecol Pathol 14(3): 255-
259, 1995. 8600078,  
32 Muraki Y, Banno K, Yanokura M, Kobayashi Y, Kawaguchi M, Nomura H, Hirasawa A, Susumu N and Aoki D: Epigenetic DNA hypermethylation: Clinical 
applications in endometrial cancer (review). Oncol Rep 22(5): 967-972, 2009. 19787208,  
33 van der Putten LJM, van Hoof R, Tops BBJ, Snijders M, van den Berg-van Erp SH, van der Wurff AAM, Bulten J, Pijnenborg JMA and Massuger L: Molecular 
profiles of benign and (pre)malignant endometrial lesions. Carcinogenesis 38(3): 329-335, 2017. 28203752, 10.1093/carcin/bgx008 
34 Zauber P, Denehy TR, Taylor RR, Ongcapin EH, Marotta S and Sabbath-Solitare M: Strong correlation between molecular changes in endometrial 
carcinomas and concomitant hyperplasia. Int J Gynecol Cancer 25(5): 863-868, 2015. 25768080, 10.1097/IGC.0000000000000421 
35 Berg A, Hoivik EA, Mjos S, Holst F, Werner HM, Tangen IL, Taylor-Weiner A, Gibson WJ, Kusonmano K, Wik E, Trovik J, Halle MK, Oyan AM, Kalland KH, 
Cherniack AD, Beroukhim R, Stefansson I, Mills GB, Krakstad C and Salvesen HB: Molecular profiling of endometrial carcinoma precursor, primary 
and metastatic lesions suggests different targets for treatment in obese compared to non-obese patients. Oncotarget 6(2): 1327-1339, 2015. 
25415225, 10.18632/oncotarget.2675 
36 Duggan BD, Felix JC, Muderspach LI, Tsao JL and Shibata DK: Early mutational activation of the c-ki-ras oncogene in endometrial carcinoma. Cancer Res 
54(6): 1604-1607, 1994. 8137266,  
37 Xiong J, He M, Hansen K, Jackson CL, Breese V, Quddus MR, Sung CJ, Lomme MM and Lawrence WD: The clinical significance of k-ras mutation in 
endometrial "surface epithelial changes" and their associated endometrial adenocarcinoma. Gynecol Oncol 142(1): 163-168, 2016. 27154241, 
10.1016/j.ygyno.2016.05.001 
38 He M, Jackson CL, Gubrod RB, Breese V, Steinhoff M, Lawrence WD and Xiong J: Kras mutations in mucinous lesions of the uterus. Am J Clin Pathol 
143(6): 778-784, 2015. 25972319, 10.1309/AJCP69RBNUHHOJRI 
39 Stewart CJ, Leung Y, Walsh MD, Walters RJ, Young JP and Buchanan DD: Kras mutations in ovarian low-grade endometrioid adenocarcinoma: Association 
with concurrent endometriosis. Hum Pathol 43(8): 1177-1183, 2012. 22305241, 10.1016/j.humpath.2011.10.009 
40 Tu Z, Gui L, Wang J, Li X, Sun P and Wei L: Tumorigenesis of k-ras mutation in human endometrial carcinoma via upregulation of estrogen receptor. 
Gynecol Oncol 101(2): 274-279, 2006. 16303170, 10.1016/j.ygyno.2005.10.016 
41 Ninomiya Y, Kato K, Takahashi A, Ueoka Y, Kamikihara T, Arima T, Matsuda T, Kato H, Nishida J and Wake N: K-ras and h-ras activation promote distinct 
consequences on endometrial cell survival. Cancer Res 64(8): 2759-2765, 2004. 15087391,  
42 Birkeland E, Wik E, Mjos S, Hoivik EA, Trovik J, Werner HM, Kusonmano K, Petersen K, Raeder MB, Holst F, Oyan AM, Kalland KH, Akslen LA, Simon R, 
Krakstad C and Salvesen HB: Kras gene amplification and overexpression but not mutation associates with aggressive and metastatic endometrial 
cancer. Br J Cancer 107(12): 1997-2004, 2012. 23099803, 10.1038/bjc.2012.477 
43 Alexander-Sefre F, Salvesen HB, Ryan A, Singh N, Akslen LA, MacDonald N, Wilbanks G and Jacobs IJ: Molecular assessment of depth of myometrial 
invasion in stage i endometrial cancer: A model based on k-ras mutation analysis. Gynecol Oncol 91(1): 218-225, 2003. 14529685,  
44 Mizuuchi H, Nasim S, Kudo R, Silverberg SG, Greenhouse S and Garrett CT: Clinical implications of k-ras mutations in malignant epithelial tumors of the 
endometrium. Cancer Res 52(10): 2777-2781, 1992. 1581890,  
45 Ito K, Watanabe K, Nasim S, Sasano H, Sato S, Yajima A, Silverberg SG and Garrett CT: K-ras point mutations in endometrial carcinoma: Effect on outcome 
is dependent on age of patient. Gynecol Oncol 63(2): 238-246, 1996. 8910634, 10.1006/gyno.1996.0313 
46 Varras MN, Koffa M, Koumantakis E, Ergazaki M, Protopapa E, Michalas S and Spandidos DA: Ras gene mutations in human endometrial carcinoma. 
Oncology 53(6): 505-510, 1996. 8960147, 10.1159/000227627 
47 Ignar-Trowbridge D, Risinger JI, Dent GA, Kohler M, Berchuck A, McLachlan JA and Boyd J: Mutations of the ki-ras oncogene in endometrial carcinoma. 
Am J Obstet Gynecol 167(1): 227-232, 1992. 1442931,  
48 Wallen M, Tomas E, Visakorpi T, Holli K and Maenpaa J: Endometrial k-ras mutations in postmenopausal breast cancer patients treated with adjuvant 
tamoxifen or toremifene. Cancer Chemother Pharmacol 55(4): 343-346, 2005. 15592834, 10.1007/s00280-004-0923-x 
49 Nagy E, Gajjar KB, Patel, II, Taylor S, Martin-Hirsch PL, Stringfellow HF, Martin FL and Phillips DH: Mgmt promoter hypermethylation and k-ras, pten and 
tp53 mutations in tamoxifen-exposed and non-exposed endometrial cancer cases. Br J Cancer 110(12): 2874-2880, 2014. 24853176, 
10.1038/bjc.2014.263 
50 Byron SA, Gartside M, Powell MA, Wellens CL, Gao F, Mutch DG, Goodfellow PJ and Pollock PM: Fgfr2 point mutations in 466 endometrioid endometrial 
tumors: Relationship with msi, kras, pik3ca, ctnnb1 mutations and clinicopathological features. PLoS One 7(2): e30801, 2012. 22383975, 
10.1371/journal.pone.0030801 
51 Alomari A, Abi-Raad R, Buza N and Hui P: Frequent kras mutation in complex mucinous epithelial lesions of the endometrium. Mod Pathol 27(5): 675-
680, 2014. 24186144, 10.1038/modpathol.2013.186 
52 Royal College of Obstetricians and Gynaecologists/British Society of Gynaecological Endoscopy Joint Guideline: Management of endometrial hyperplasia. 
Green-top Guideline No. 67(2016).  
 
